Cargando…

Rapid VAC high dose melphalan regimen, a novel chemotherapy approach in childhood soft tissue sarcomas.

Forty-three children with malignant soft tissue sarcomas (IRS Groups II-IV) were treated with rapid dose delivery chemotherapy protocol comprising six courses of vincristine, adriamycin and cyclophosphamide, given in most cases within 8 weeks (Rapid VAC). This was followed in 36 patients by high dos...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pinkerton, C. R., Groot-Loonen, J., Barrett, A., Meller, S. T., Tait, D., Ashley, S., McElwain, T. J.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1991
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977493/ https://www.ncbi.nlm.nih.gov/pubmed/1892770

Ejemplares similares

'VEEP' in children with Hodgkin's disease--a regimen to decrease late sequelae.
por: O'Brien, M. E., et al.
Publicado: (1992)

High-dose melphalan with autologous marrow for treatment of advanced neuroblastoma.
por: Pritchard, J., et al.
Publicado: (1982)

Cyclophosphamide priming reduces intestinal damage in man following high dose melphalan chemotherapy.
por: Selby, P. J., et al.
Publicado: (1987)

'JEB'--a carboplatin based regimen for malignant germ cell tumours in children.
por: Pinkerton, C. R., et al.
Publicado: (1990)

Effect of high-dose melphalan on marrow and intestinal epithelium in mice pretreated with cyclophosphamide.
por: Millar, J. L., et al.
Publicado: (1978)

Verapamil potentiation of melphalan cytotoxicity and cellular uptake in murine fibrosarcoma and bone marrow.
por: Robinson, B. A., et al.
Publicado: (1985)

Effects of verapamil and alcohol on blood flow, melphalan uptake and cytotoxicity, in murine fibrosarcomas and human melanoma xenografts.
por: Robinson, B. A., et al.
Publicado: (1986)

Epidermal growth factor (hEGF) has no effect on murine intestine epithelial damage and regeneration after melphalan.
por: Robinson, B. A., et al.
Publicado: (1985)

High dose melphalan, BCNU and etoposide with autologous bone marrow transplantation for Hodgkin's disease.
por: Zulian, G. B., et al.
Publicado: (1989)

Outcome of children with resistant and relapsed Hodgkin's disease.
por: James, N. D., et al.
Publicado: (1992)

Treatment of advanced malignant melanoma with high-dose melphalan and autologous bone marrow transplantation.
por: Cornbleet, M. A., et al.
Publicado: (1983)

Childhood rhabdomyosarcoma: experience of the Children's Solid Tumour Group.
por: Kingston, J. E., et al.
Publicado: (1983)

The effects of melphalan and misonidazole on the vasculature of a murine sarcoma.
por: Murray, J. C., et al.
Publicado: (1987)

Busulfan plus melphalan versus melphalan alone conditioning regimen after bortezomib based triplet induction chemotherapy for patients with newly diagnosed multiple myeloma
por: Park, Songyi, et al.
Publicado: (2021)

Active immunotherapy as an adjunct to chemotherapy in the treatment of disseminated malignant melanoma: a pilot study.
por: Currie, G. A., et al.
Publicado: (1975)

Five years' experience with ChlVPP: effective low-toxicity combination chemotherapy for Hodgkin's disease.
por: Dady, P. J., et al.
Publicado: (1982)

Marrow autotransplantation accelerates haematological recovery in patients with malignant melanoma treated with high-dose melphalan.
por: McElwain, T. J., et al.
Publicado: (1979)

Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
por: Rodriguez, Tulio E., et al.
Publicado: (2016)

Intravitreal Melphalan Chemotherapy for Vitreous Seeds in Retinoblastoma
por: Yousef, Yacoub A., et al.
Publicado: (2020)

Etoposide and adriamycin containing combination chemotherapy (HOPE-Bleo) for relapsed Hodgkin's disease.
por: Perren, T. J., et al.
Publicado: (1990)

Isolated Limb Perfusion with Melphalan and TNF-α in the Treatment of Extremity Sarcoma
por: Verhoef, Cornelis, et al.
Publicado: (2007)

Busulfan plus melphalan versus high-dose melphalan as conditioning regimens in autologous stem cell transplantation for newly diagnosed multiple myeloma
por: Byun, Ja Min, et al.
Publicado: (2018)

Isolated Limb Perfusion with Tumor Necrosis Factor Alpha and Melphalan for Locally Advanced Soft Tissue Sarcoma: Three Time Periods at Risk for Amputation
por: van Ginkel, Robert J., et al.
Publicado: (2007)

The pathologic response of resected synovial sarcomas to hyperthermic isolated limb perfusion with melphalan and TNF-α: a comparison with the whole group of resected soft tissue sarcomas
por: Schwindenhammer, Benjamin, et al.
Publicado: (2013)

Melphalan intra-arterial chemotherapy for choroidal melanoma chemoreduction
por: Jorge, Rodrigo, et al.
Publicado: (2022)

Chemotherapy for malignant melanoma: combinations and high doses produce more responses without survival benefit.
por: Lakhani, S., et al.
Publicado: (1990)

Colony growth and clonogenic cell survival in human melanoma xenografts treated with chemotherapy.
por: Selby, P. J., et al.
Publicado: (1980)

Bortezomib and melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma
por: Lee, Se Ryeon, et al.
Publicado: (2010)

Mitoxantrone-melphalan conditioning regimen for autologous stem cell transplantation in relapsed/refractory lymphoma
por: OKAY, Müfide, et al.
Publicado: (2019)

Childhood soft-tissue sarcoma associated with Sotos syndrome
por: Hill, Destin E., et al.
Publicado: (2015)

High dose BCNU chemotherapy with autologous bone marrow transplantation and full dose radiotherapy for grade IV astrocytoma.
por: Mbidde, E. K., et al.
Publicado: (1988)

Safety and Efficacy of Intravitreal Chemotherapy (Melphalan) to Treat Vitreous Seeds in Retinoblastoma
por: Yousef, Yacoub A., et al.
Publicado: (2021)

Efficacy and Safety of High-Dose Chemotherapy with Treosulfan and Melphalan in Multiple Myeloma
por: Gillich, Cédric, et al.
Publicado: (2023)

Adjuvant Chemotherapy of Soft Tissue Sarcoma—Current Status
por: Judson, Ian
Publicado: (2000)

Controversies and consensus of neoadjuvant chemotherapy in soft-tissue sarcomas
por: Loong, Herbert H., et al.
Publicado: (2018)

Clinical Benefit of Second-Line Palliative Chemotherapy in Advanced Soft-Tissue Sarcoma
por: Minchom, Anna, et al.
Publicado: (2010)

Secondary CIC-rearranged sarcoma responsive to chemotherapy regimens for Ewing sarcoma: A case report
por: Kimbara, Shiro, et al.
Publicado: (2021)

Fourteen-Day Gemcitabine-Docetaxel Chemotherapy Is Effective and Safer Compared to 21-Day Regimen in Patients with Advanced Soft Tissue and Bone Sarcoma
por: Pan, Minggui, et al.
Publicado: (2021)

Decreased melphalan accumulation in a human breast cancer cell line selected for resistance to melphalan.
por: Moscow, J. A., et al.
Publicado: (1993)

Microdialysis and response during regional chemotherapy by isolated limb infusion of melphalan for limb malignancies
por: Thompson, J F, et al.
Publicado: (2001)

Cannot write session to /tmp/vufind_sessions/sess_7h9mq8d39d2lih0e451ftp1t77